B 注脱酸酯 (BA) 是松科植物精油中的一种化学成分，其治疗自身免疫疾病等多种疾病的药理作用尚未得到积极研究。本研究旨在探讨 BA 对髓鞘寡碳水化合物 (MOG35-55) 诱导的实验性自身免疫性脑脊髓炎 (EAE) 小鼠的药理学效应和分子机制，以 EAE 小鼠为多发性硬化 (MS) 的动物模型，并保持翻译前的原句结构。在 EAE 症状的起始阶段 (第8天) ，将 BA (100、200 或 400 毫克/千克) 每日口服一次，共30天，进行行为测试以及第16-18天进行组织病理学和分子分析。BA 缓解了与代表性促炎性细胞因子 (白细胞介素(IL)-1β、IL-6和肿瘤坏死因子-α)、酶 (环氧合酶-2 、诱导型一氧化氮合酶) 和趋化因子 (单核细胞趋化蛋白-1、巨噬细胞炎性蛋白-1α 和激活调节) 的下调相关的脊髓神经元脱髓鞘和行为紊乱 (运动障碍)、减少了小胶质细胞 (CD11b+/CD45+(low)) 和巨噬细胞 (CD11b+/CD45+(high)) 的浸润。BA 的抗炎作用与丝裂原活化蛋白激酶和核因子-κB通路的抑制有关。BA 还减少了 CD4+T、Th1 和 Th17 细胞进入EAE 小鼠脊髓的招募/浸润速率，这与降低了血-脊髓屏障(BSCB)破坏有关。这些发现强烈表明，由于其抗炎和 BSCB 保护作用，BA 可以缓解EAE，表明 BA 是治疗自身免疫性脱髓鞘疾病，包括MS的潜在治疗药物。 版权所有©2022 Elsevier GmbH。保留所有权利。

Bornyl acetate (BA), a chemical component of essential oil in the Pinus family, has yet to be actively studies in terms of its therapeutic effect on numerous diseases, including autoimmune diseases.This study aimed to investigate the pharmacological effects and molecular mechanisms of BA on myelin oligodendrocyte glycoprotein (MOG35-55)-induced experimental autoimmune encephalomyelitis (EAE) mice in an animal model of multiple sclerosis (MS), a representative autoimmune disease in central nervous system.BA (100, 200, or 400 mg/kg) was orally treated to EAE mice once daily for 30 days after immunization for the behavioral test and for the 16th-18th days for the histopathological and molecular analyses, from the onset stage (8th day) of EAE symptoms.BA mitigated behavioral dysfunction (motor disability) and demyelination in the spinal cord that were associated with the down-regulation of representative pro-inflammatory cytokines (interleukin (IL)-1 beta, IL-6, and tumor necrosis factor-alpha), enzymes (cyclooxygenase-2 and inducible nitric oxide synthase), and chemokines (monocyte chemotactic protein-1, macrophage inflammatory protein-1 alpha, and regulated on activation), and decreased infiltration of microglia (CD11b+/CD45+(low)) and macrophages (CD11b+/CD45+(high)). The anti-inflammatory effect of BA was related to the inhibition of mitogen-activated protein kinases and nuclear factor-kappa B pathways. BA also reduced the recruitment/infiltration rates of CD4+ T, Th1, and Th17 cells into the spinal cords of EAE mice, which was related to reduced blood-spinal cord barrier (BSCB) disruption.These findings strongly suggest that BA may alleviate EAE due to its anti-inflammatory and BSCB protective activities. This indicates that BA is a potential therapeutic agent for treating autoimmune demyelinating diseases including MS.Copyright © 2022 Elsevier GmbH. All rights reserved.